Imagen de Portada

Impact of 68Ga-FAPi PET/CT on Staging or Restaging Digestive System Tumors in Patients with Negative or Equivocal 18F-FDG PET/CT Findings

Guardado en:
Publicado en:Molecular Imaging and Radionuclide Therapy vol. 34, no. 1 (Feb 2025), p. 31
Autor principal: Selçuk, Nalan Alan
Otros Autores: Beydağı, Gamze, Akçay, Kaan, Demirci, Emre, Görmez, Ayşegül, Bala, Başak Öven, Çelik, Serkan, Şen, Fatma, Kapar, Özge, Kabasakal, Levent
Publicado:
Galenos Publishing House
Materias:
Cancer
Tomography
Metastasis
Digestive system
Medical imaging
Lesions
Tumors
Fibroblast activation protein
Chromatography
Metastases
Positron emission tomography
Carcinoma
Statistical analysis
Patients
Fibroblasts
Computed tomography
Magnetic resonance imaging
Lymphatic system
Positron emission
Fluorine isotopes
Effectiveness
Biomarkers
Colorectal carcinoma
Gastric cancer
Lymph nodes
Malignancy
Avidity
Gastrointestinal diseases
Acceso en línea:Citation/Abstract
Full Text
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Resumen:ObjectivesThis study aimed to evaluate the potential efficacy of 68Ga-fibroblast activation protein inhibitor (FAPi) positron emission tomography/computed tomography (PET/CT) for detecting, staging, and restaging digestive system malignancies that are 18F-fluorodeoxyglucose (18F-FDG) negative or show equivocal 18F-FDG uptake.MethodsWe conducted a prospective analysis of 30 patients with pathologically confirmed primary tumors or metastases of the digestive system. Participants underwent 68Ga-FAPi PET/CT and 18F-FDG PET/CT imaging for staging or restaging purposes within the same week. The efficacy of 68Ga-FAPi PET/CT was assessed by comparing its ability to detect lesions and influence disease staging with that of 18F-FDG PET/CT.Results68Ga-FAPi PET/CT imaging was performed in 30 patients with 18F-FDG-negative or indeterminate lesions. Of the 30 patients, 23 had gastric cancer and 7 had colorectal cancer. Among all patients, histopathological diagnosis of signet ring cell carcinoma was present in 15 (50%) patients. Primary tumor or local recurrence was detected in 19 (63%) patients, lymph node metastasis in 8 (27%) patients, visceral metastasis in 4 (13%) patients, peritoneal metastasis in 14 (47%) patients, and bone metastasis in 3 (10%) patients on 68Ga-FAPi PET/CT images. All patients underwent histopathological confirmation on 68Ga-FAPi PET/CT images. The disease stage was upgraded in 20 patients (67%) after 68Ga-FAPi PET/CT imaging. Of the 20 patients, 12 had no evidence of recurrence or metastasis on 18F-FDG PET/CT.ConclusionBased on our study, 68Ga-FAPi PET/CT alters the disease stage in the majority of gastrointestinal malignancies with negative or equivocal 18F-FDG PET/CT findings. 68Ga-FAPi PET/CT appears to be effective in both staging and restaging of gastrointestinal malignancies, such as signet-ring cell carcinomas of the stomach that frequently show low 18F-FDG -avidity.
ISSN:2146-1414
2147-1959
DOI:10.4274/mirt.galenos.2024.50470
Fuente:Health & Medical Collection